NCT03759184 2022-03-22Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte LeukemiaNational Institutes of Health Clinical Center (CC)Phase 1 Terminated1 enrolled 13 charts